In a recent article, entitled, “Immune tolerance-adjusted personalized immunogenicity prediction for Pompe disease,” Anne S. De Groot, MD, of EpiVax, Inc., and the Center for Vaccines and Immunology, University of Georgia, and colleagues discuss a study designed to develop a tool for personalized immunogenicity risk assessment. This tool quantifies T cell epitopes that differ between recombinant human GAA and native GAA using information about the native gene and an individual's HLA DR haplotype to predict the risk of developing anti-drug antibodies. The authors hypothesize that an improved understanding of immunogenicity risk will facilitate the implementation of targeted approaches that may improve overall clinical outcomes by minimizing the development of anti-drug antibodies.